Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/13199
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYoung R
dc.contributor.authorMainwaring P
dc.contributor.authorClingan P
dc.contributor.authorParnis FX
dc.contributor.authorAsghari G
dc.contributor.authorBeale P
dc.contributor.authorAly A
dc.contributor.authorBotteman M
dc.contributor.authorRomano A
dc.contributor.authorFerrara S
dc.contributor.authorMargunato-Debay S
dc.contributor.authorHarris M.
dc.date.accessioned2020-06-25T19:28:58Z-
dc.date.available2020-06-25T19:28:58Z-
dc.date.issued2018
dc.identifier.citationAsia Pac J Clin Oncol. 2018 Oct;14(5):e325-e331. doi: 10.1111/ajco.12999. Epub 2018 Jun 22.
dc.identifier.urihttp://docs.prosentient.com.au/prosentientjspui/handle/1/13199-
dc.language.isoen
dc.titlenab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
dc.identifier.doi10.1111/ajco.12999
dc.identifier.journaltitleAsia Pac J Clin Oncol
dc.identifier.pubmedid29932294
Appears in Collections:ISLHD research

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing

Pubmed

PubMed References

Who's citing